Product
5-Aminolevulinic Acid
Aliases
5-ALA, 5 Aminolevulinic Acid, Gleolan
Name
GLEOLAN
INN Name
AMINOLEVULINIC ACID HYDROCHLORIDE
FDA Approved
Yes
3 clinical trials
2 organizations
15 indications
1 document
Indication
High-Grade GliomaIndication
Brain TumorIndication
PediatricIndication
GliomaIndication
malignantIndication
CancerIndication
NeuroepithelialIndication
Neuroectodermal TumorsIndication
Photosensitizing AgentsIndication
Malignant NeoplasmsIndication
Brain NeoplasmsIndication
AdultIndication
Central Nervous System NeoplasmsIndication
TumorIndication
ResidualClinical trial
A Phase 1 Multi-center Clinical Trial Evaluating the Safety and Tolerability of 5-aminolevulinic Acid (5-ALA) Combined With CV01 Delivery of Ultrasound for Sonodynamic Therapy(SDT) in Patients With Recurrent High Grade Glioma (HGG)Status: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
Clinical Safety Study on 5-Aminolevulinic Acid (5-ALA) in Children and Adolescents With Supratentorial Brain TumorsStatus: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
5-Aminolevulinic Acid (5-ALA) Gliolan®: Usage Increase Proposal for Neurosurgical Procedures in High-Grade GliomasStatus: Not yet recruiting, Estimated PCD: 2026-05-31
Document
DailyMed Label: GLEOLANOrganization
NX DEVELOPMENT CORPOrganization
Medexus Pharma, Inc.